TNF and rheumatoid arthritis: In a phase 3 clinical trial (NCT05428488), the level of rheumatoid arthritis remission in the group treated with TNF-α inhibitors is a reference to the efficiency of treatment consisting of abatacept, which is a soluble cytotoxic T lymphocyte antigen 4 (CTLA-4).